LeMaitre Vascular (NASDAQ:LMAT) Downgraded by StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

LMAT has been the subject of several other research reports. Barrington Research upped their price target on LeMaitre Vascular from $66.00 to $69.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. KeyCorp began coverage on LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $68.20.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $63.04 on Tuesday. LeMaitre Vascular has a 12 month low of $44.27 and a 12 month high of $74.64. The business has a 50 day simple moving average of $64.95 and a 200-day simple moving average of $57.72. The stock has a market capitalization of $1.41 billion, a PE ratio of 47.63, a price-to-earnings-growth ratio of 2.78 and a beta of 0.87.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 EPS for the quarter, topping the consensus estimate of $0.36 by $0.02. LeMaitre Vascular had a return on equity of 10.57% and a net margin of 15.56%. The business had revenue of $48.90 million during the quarter, compared to analysts’ expectations of $49.01 million. During the same quarter in the prior year, the business earned $0.25 earnings per share. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. As a group, equities research analysts anticipate that LeMaitre Vascular will post 1.66 EPS for the current year.

Insider Buying and Selling

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 36,600 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $68.03, for a total value of $2,489,898.00. Following the sale, the chief executive officer now owns 2,187,526 shares of the company’s stock, valued at $148,817,393.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the sale, the director now owns 2,278 shares of the company’s stock, valued at $157,182. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 36,600 shares of the company’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the sale, the chief executive officer now directly owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock valued at $7,873,749 over the last quarter. Company insiders own 12.50% of the company’s stock.

Institutional Trading of LeMaitre Vascular

Several large investors have recently bought and sold shares of LMAT. West Tower Group LLC boosted its stake in shares of LeMaitre Vascular by 201.3% during the fourth quarter. West Tower Group LLC now owns 467 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 312 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of LeMaitre Vascular by 555.3% during the first quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 522 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in shares of LeMaitre Vascular during the third quarter valued at $31,000. FMR LLC boosted its stake in shares of LeMaitre Vascular by 111.7% during the first quarter. FMR LLC now owns 633 shares of the medical instruments supplier’s stock valued at $33,000 after acquiring an additional 334 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of LeMaitre Vascular during the third quarter valued at $38,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.